Seer and Korea University launch a study to identify blood-based cancer biomarkers using advanced mass spectrometry and AI analytics. Seer, Inc. and Korea University have launched a groundbreaking ...
REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the publication in Nature ...
Seer, Inc. will present innovative findings at the 21st Annual US Human Proteome Organization (HUPO) Conference in Philadelphia from February 22-26, 2025, where they will highlight advancements in ...
REDWOOD CITY, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (SEER) (NASDAQ: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced ...
REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the publication in Nature ...
Application of a Data Quality Framework to Ductal Carcinoma In Situ Using Electronic Health Record Data From the All of Us Research Program Categorizing patients with cancer by their disease stage can ...
This featured session will highlight how multi-omic approaches powered by Seer’s Proteograph Product Suite are transforming translational genomics and clinical research. Brendan Keating, PhD, ...
At ASHG, Seer showcased its Proteograph product suite which it claims delivers proteomic insights that complement and strengthen other forms of omics data. Through various sessions at the meeting, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback